MDCXW Medicus Pharma Ltd. - Warrant
$0,68
Fiyat · May 19, 2026
Temel veriler itibarıyla Nis 29, 2026
52 Haftlık Aralık
$1–$2
5% of range
Analist Derecelendirmesi
—
Fiyat Hedefi
—
P/E (TTM)
-0.9
ROE
—
Net Kâr Marjı
—
MDCXW Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$0.68
Piyasa Değeri
—
P/E (TTM)
-0.9
EPS (TTM)
$-2.74
Gelir (TTM)
—
Temettü Verimi
—
ROE
—
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$1 – $3
MDCXW Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
—
Hisse Başına Kâr
$-2.74
2023-12-31
→
2025-12-31
Serbest Nakit Akışı
—
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
MDCXW
Akran Ortalaması
P/E (TTM)
-0.9
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
MDCXW
Akran Ortalaması
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
MDCXW
Akran Ortalaması
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
MDCXW
Akran Ortalaması
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
MDCXW
Akran Ortalaması
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 11
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| R&D Expense | $8M | $4M | $193.6K | |
| SG&A Expense | $18M | $8M | $5M | |
| Operating Expenses | $34M | $11M | $5M | |
| Operating Income | $-34M | $-11M | $-5M | |
| Other Non-op | $-1M | $25.4K | $-584.8K | |
| Income Tax | $0 | $0 | $0 | |
| Net Income | $-47M | $-11M | $-5M | |
| EPS (Basic) | $-2.74 | $-1.16 | $-1.53 | |
| EPS (Diluted) | $-2.74 | $-1.16 | $-1.53 | |
| Shares (Basic) | 17,283,824 | 9,619,184 | 3,479,494 | |
| Shares (Diluted) | 17,283,824 | 9,619,184 | 3,479,494 |
Bilanço 15
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & Equivalents | $9M | $4M | $2M | |
| Prepaid Expense | $1M | $1M | $173.7K | |
| Current Assets | $10M | $5M | $2M | |
| Total Assets | $10M | $6M | $2M | |
| Accounts Payable | $3M | $1M | $210.8K | |
| Current Liabilities | $10M | $2M | $781.6K | |
| Capital Leases | $60.1K | $205.9K | $0 | |
| Total Liabilities | $10M | $3M | $781.6K | |
| Common Stock | $57M | $31M | $19M | |
| Paid-in Capital | $7M | $2M | $98.6K | |
| Retained Earnings | $-64M | $-29M | $-18M | |
| AOCI | $10.9K | $0 | · | |
| Stockholders' Equity | $-67.6K | $3M | $1M | |
| Liabilities + Equity | $10M | $6M | $2M | |
| Shares Outstanding | 25,176,303 | 11,816,721 | 8,076,673 |
Nakit Akışı 7
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Stock-based Comp | $2M | $713.1K | $98.6K | |
| Deferred Tax | $0 | $0 | · | |
| Operating Cash Flow | $-23M | $-10M | $-4M | |
| Investing Cash Flow | $-5M | $0 | · | |
| Stock Issued | $10M | $5M | $0 | |
| Financing Cash Flow | $32M | $13M | $6M | |
| Net Change in Cash | $5M | $2M | · |
Değerleme (TTM) 4
| Metrik | Eğilim | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue TTM | $-197.4K | $25.4K | · | |
| Net Income TTM | $-47M | $-11M | · | |
| P/E | -0.9 | · | · | |
| Earnings Yield | -109.6% | · | · |
Gelir Tablosu 11
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| R&D Expense | $3M | $2M | $1M | $2M | $1M | |
| SG&A Expense | $10M | $5 | $5M | $3M | $2M | |
| Operating Expenses | $23M | $15 | $6M | $5M | $4M | |
| Operating Income | $-23M | $-15 | $-6M | $-5M | $-4M | |
| Other Non-op | $-394.0K | $-555.0K | $-160.0K | $23.9K | $48.9K | |
| Net Income | $-15M | $-21M | $-6M | $-5M | $-4M | |
| EPS (Basic) | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | |
| EPS (Diluted) | $-0.77 | $-1.12 | $-0.43 | $-0.42 | $-0.27 | |
| Shares (Basic) | -27,872,542 | 18,631,668 | 14,284,261 | 12,240,437 | -16,140,220 | |
| Shares (Diluted) | -27,872,542 | 18,631,668 | 14,284,261 | 12,240,437 | -16,140,220 | |
| EBITDA | · | $-15 | $-6M | $-5M | · |
Bilanço 15
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $9M | $9M | $10M | $4M | $4M | |
| Prepaid Expense | $1M | $1M | $1M | $1M | $1M | |
| Current Assets | $10M | $10M | $11M | $5M | $5M | |
| Total Assets | $10M | $10M | $12M | $6M | $6M | |
| Accounts Payable | $3M | $2M | $2M | $2M | $1M | |
| Current Liabilities | $10M | $11M | $9M | $3M | $2M | |
| Capital Leases | $60.1K | $95.2K | $141.8K | $174.4K | $205.9K | |
| Total Liabilities | $10M | $11M | $9M | $4M | $3M | |
| Common Stock | $57M | $4 | $38M | $33M | $31M | |
| Paid-in Capital | $7M | $6M | $6M | $3M | $2M | |
| Retained Earnings | $-64M | $-5 | $-40M | $-34M | $-29M | |
| AOCI | $10.9K | $10.7K | · | · | $0 | |
| Stockholders' Equity | $-67.6K | $-910.1K | $3M | $2M | $3M | |
| Liabilities + Equity | $10M | $10M | $12M | $6M | $6M | |
| Shares Outstanding | 25,176,303 | 20,971,122 | 15,936,266 | 13,417,561 | 11,816,721 |
Nakit Akışı 6
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Stock-based Comp | $429.7K | $852.8K | $117.4K | $112.3K | $91.7K | |
| Operating Cash Flow | $-7M | $-7M | $-5M | $-4M | $-3M | |
| Investing Cash Flow | $0 | · | · | · | $0 | |
| Stock Issued | $0 | · | · | · | $0 | |
| Financing Cash Flow | $7M | $10M | $11M | $4M | $2M | |
| Net Change in Cash | $43.1K | · | · | · | $-1M |
Kârlılık 5
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Operating Margin | · | -0.13% | -15038.7% | · | · | |
| Net Margin | · | -180917.3% | · | · | · | |
| EBITDA Margin | · | -0.13% | -15038.7% | · | · | |
| ROA | · | -419.7% | · | -180.4% | · | |
| ROE | · | 4600.6% | · | -475.2% | · |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Current Ratio | · | 0.9 | 1.3 | 1.5 | · | |
| Quick Ratio | · | 0.8 | 1.1 | 1.2 | · |
Verimlilik 1
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | 0.0 | · | · |
Değerleme (TTM) 5
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Market Cap | · | $52M | $40M | · | · | |
| P/E | · | -1.1 | -1.6 | · | · | |
| P/B | · | -57.6 | 12.3 | · | · | |
| P / Tangible Book | · | · | 12.3 | · | · | |
| Earnings Yield | · | -88.4% | -61.2% | · | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | |
|---|---|---|---|
| Net Gelir | $-47M | $-11M | $-5M |
| Seyreltilmiş Hisse Başı Kâr | $-2.74 | $-1.16 | $-1.53 |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.